Are Natriuretic Peptides Just Markers or Active Players in Heart Disease?

Cardiac natriuretic peptides are not merely passive biomarkers — they actively participate in cardiovascular pathophysiology through vasodilation, natriuresis, and neurohormonal suppression, making them both diagnostic tools and therapeutic targets.

Clerico, Aldo·Clinical chemistry and laboratory medicine·2002·Strong EvidenceReview
RPEP-00719ReviewStrong Evidence2002RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Natriuretic peptides serve dual roles as sensitive cardiac biomarkers AND active cardiovascular protectors, with evidence supporting both diagnostic utility and therapeutic potential through their vasodilatory, natriuretic, and neurohormonal-suppressive actions.

Key Numbers

How They Did This

Review synthesizing diagnostic/prognostic biomarker data with physiological/therapeutic evidence for natriuretic peptide cardiovascular effects.

Why This Research Matters

Understanding that natriuretic peptides are active protectors (not just markers) justifies therapies that boost them — the scientific basis for sacubitril/valsartan (Entresto).

The Bigger Picture

The realization that biomarkers can also be therapeutic targets transformed cardiology. BNP isn't just telling us the heart is failing — it's trying to fix the problem. Boosting this natural defense (with Entresto) helps the heart heal.

What This Study Doesn't Tell Us

The relative therapeutic contribution of boosted natriuretic peptides versus reduced angiotensin is still debated for drugs like Entresto.

Questions This Raises

  • ?How much of Entresto's benefit comes from boosted natriuretic peptides versus reduced angiotensin?
  • ?Could direct natriuretic peptide infusion outperform Entresto?
  • ?Are there other biomarkers that are also active disease mediators?

Trust & Context

Key Stat:
Markers AND mediators Natriuretic peptides don't just measure heart failure — they fight it through vasodilation and hormone suppression, justifying therapies that boost them
Evidence Grade:
Strong evidence from a comprehensive review integrating decades of diagnostic, physiological, and therapeutic research on natriuretic peptides.
Study Age:
Published in 2002. This dual-role concept was validated by Entresto's clinical success in boosting natriuretic peptides for heart failure treatment.
Original Title:
Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease?
Published In:
Clinical chemistry and laboratory medicine, 40(8), 752-60 (2002)
Authors:
Clerico, Aldo(2)
Database ID:
RPEP-00719

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Is BNP just a blood test or does it actually do something?

Both. BNP is released by the stressed heart (making it a useful blood test) AND it actively protects the heart by relaxing blood vessels and reducing fluid retention. It's the heart's own defense mechanism.

Is this why Entresto works?

Yes. Entresto prevents BNP from being broken down, boosting the heart's own protective peptide system. The drug doesn't just measure the problem — it amplifies the body's natural solution.

Read More on RethinkPeptides

Cite This Study

RPEP-00719·https://rethinkpeptides.com/research/RPEP-00719

APA

Clerico, Aldo. (2002). Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease?. Clinical chemistry and laboratory medicine, 40(8), 752-60.

MLA

Clerico, Aldo. "Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease?." Clinical chemistry and laboratory medicine, 2002.

RethinkPeptides

RethinkPeptides Research Database. "Pathophysiological and clinical relevance of circulating lev..." RPEP-00719. Retrieved from https://rethinkpeptides.com/research/clerico-2002-pathophysiological-and-clinical-relevance

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.